Members of the Polish Military Contingent (PMC) have been stationed in Afghanistan since 2002. They typically serve in areas characterised by low standards of sanitation which often leads to the development of food- and waterborne diseases. The aim of the study was to evaluate the prevalence of Giardia intestinalis infections among Polish soldiers deployed to Afghanistan. The research study was conducted as part of a programme for prevention of parasitic diseases of the gastrointestinal tract run by the Polish Armed Forces. The study was carried out in August 2011; it involved 630 asymptomatic Polish soldiers serving in the Forward Operational Base (FOB) Ghazni in eastern Afghanistan. Stool specimens obtained from members of the PMC were first tested in FOB Ghazni (detection of Giardia intestinalis by Rida Quick Giardia immunochromatographic tests and Ridascreen Giardia immunoenzymatic tests - single samples). Next, the same biological material and two other faecal specimens fixed in 10% formalin were transported to the Military Institute of Medicine in Poland, where they were tested for Giardia intestinalis under light microscopy (direct smear, decantation in distilled water). Parasitological tests performed under light microscopy showed that 2.7% (17/630) of the study group were infected with Giardia intestinalis. Some of these results were confirmed by immunochromatographic tests (6/630). In contrast, immunoenzymatic tests (ELISA) demonstrated a significantly higher detection rate reaching 18.1% (114/630). Immunoenzymatic tests confirmed all the positive results given by light microscopy and by immunochromatographic tests. The prevalence rate of Giardia intestinalis infections in Polish soldiers deployed to Afghanistan was found to be high. Microscopic methods exhibit low sensitivity and therefore may result in the underestimation of the true parasite prevalence. Immunoenzymatic tests (ELISA) showing a much higher sensitivity in comparison to light microscopy and immunochromatographic tests ought to be applied in screening for intestinal protozoan infections in areas characterised by harsh environmental conditions.
1 April 2021 in The Journal of Steroid Biochemistry and Molecular Biology
Pediatric metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a major public health concern. The pediatric form of MASLD differs from the adult phenotype in its pathophysiology and exhibits distinct histopathological characteristics. This study aimed to characterize serum metabolomic alterations associated with pediatric MASLD and to identify metabolic signatures that may provide further insight into the disease phenotype. To this end, untargeted metabolomic analysis was performed on serum samples from 21 pediatric MASLD patients and 22 healthy controls using liquid chromatography coupled with high-resolution quadrupole time-of-flight mass spectrometry (LC-MS/QTOF). Univariate statistical analysis was performed using the Mann–Whitney U-test with false discovery rate (FDR) correction, while multivariate analysis employed principal component analysis and orthogonal partial least squares discriminant analysis (OPLS-DA). Multivariate analysis in the positive ionization mode demonstrated clear separation between the MASLD and control groups (R2Y = 0.972, Q2 = 0.823, CV-ANOVA p-value = 2.387 × 10−10). A total of 46 annotated metabolites differed significantly between the groups. The most pronounced alterations involved bile acid and sterol metabolism, including increased 12α-hydroxy-3-oxocholadienic acid and decreased conjugated primary bile acids, including taurine and glycine conjugates. In addition, increased levels of free carnitine and short-chain acylcarnitines, together with alterations in free and oxidized fatty acids, suggested disturbances in fatty acid metabolism. The metabolomic profile also revealed broad disruption of glycerophospholipid metabolism, characterized primarily by decreased lysophosphatidylcholines and lysophosphatidylethanolamines. In conclusion, the metabolomic profile of pediatric MASLD indicates pronounced systemic metabolic alterations, primarily involving lipid and fatty acid metabolism, bile acid and sterol metabolism, and amino acid-related pathways. The coordinated pattern of these changes suggests alterations across multiple interconnected metabolic processes, highlighting the complex metabolic phenotype of pediatric MASLD. The identified metabolic signatures provide a basis for further investigation and warrant validation in larger, independent cohorts to determine their biological and potential clinical relevance.